ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation
Phase 4
Completed
- Conditions
- Kidney TransplantationKidney Failure, ChronicRenal Insufficiency, Chronic
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2009-04-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 50
- Registration Number
- NCT00717379
A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients
Phase 3
Completed
- Conditions
- Kidney TransplantationTransplantation ImmunologyHost vs Graft Reaction
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 73
- Registration Number
- NCT00717678
A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection
Phase 4
Completed
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1252
- Registration Number
- NCT00717470
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 128
- Registration Number
- NCT00698243
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇧🇪University Hospitals Leuven, Leuven, Belgium
🇬🇧Royal Mardsen Hospital, Sutton, Surrey, United Kingdom
Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX
Phase 2
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 94
- Registration Number
- NCT00693524
Mycophenolate Mofetil (MMF) Discontinuation From a Tacrolimus/MMF/Steroid Triple Regimen After Kidney Transplantation
Phase 3
Completed
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 152
- Registration Number
- NCT00693381
Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 175
- Registration Number
- NCT00692172
Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 166
- Registration Number
- NCT00691262
Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 350
- Registration Number
- NCT00691145
Protopic Ointment in Children Atopic Eczema
Phase 4
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 487
- Registration Number
- NCT00689832
© Copyright 2025. All Rights Reserved by MedPath